Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry
Laurent Coudeville, Gabriela B. Gomez, Ombeline Jollivet, Rebecca C. Harris, Edward W. Thommes, Sophie Druelles, Ayman Chit, Sandra S. Chaves, C Mahé
Abstract
• Understanding uncertainty in the COVID-19 pandemic is a priority for the industry. • Policy and population behavioral affect risk management in the short/mid-term. • Information around natural history unknowns will guide long-term risk management. • Our framework allows risk management and risk-sharing strategies discussions.
Topics & Concepts
PandemicPerspective (graphical)Coronavirus disease 2019 (COVID-19)Risk managementPharmaceutical industryRisk analysis (engineering)Risk assessmentTerm (time)PopulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVaccinationBusinessMedicineEnvironmental healthComputer scienceEconomicsVirologyOutbreakDiseaseManagementInfectious disease (medical specialty)Quantum mechanicsPathologyFinancePharmacologyPhysicsArtificial intelligenceCOVID-19 epidemiological studiesSARS-CoV-2 and COVID-19 ResearchViral Infections and Outbreaks Research